Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55.7M
-
Number of holders
-
87
-
Total 13F shares, excl. options
-
19.1M
-
Shares change
-
+940K
-
Total reported value, excl. options
-
$370M
-
Value change
-
+$23.9M
-
Put/Call ratio
-
1.45
-
Number of buys
-
53
-
Number of sells
-
-36
-
Price
-
$19.39
Significant Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q4 2020
107 filings reported holding SPRO - Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2020.
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) has 87 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.1M shares
of 55.7M outstanding shares and own 34.27% of the company stock.
Largest 10 shareholders include Aquilo Capital Management, LLC (3.93M shares), BVF INC/IL (2.24M shares), BlackRock Inc. (1.73M shares), Atlas Venture Associates IX, LLC (1.38M shares), Atlas Venture Associates IX, LLC (1.38M shares), Rock Springs Capital Management LP (1.24M shares), VANGUARD GROUP INC (1.13M shares), Alphabet Inc. (890K shares), Novo Holdings A/S (577K shares), and Artal Group S.A. (500K shares).
This table shows the top 87 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.